glp 1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits GLP-1 receptor agonists and DPP-4

Cell Death Dis (2013) 4:e612

2009;11(Suppl 3):1118

Wadden TA, Foreyt JP, Foster GD, et al

Furthermore, in the subgroup analysis, the authors only discussed the primary outcomes (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) and did not perform a subgroup analysis of the association between semaglutide, placebo, and DR

Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study

Wegovy coverage under Blue Cross Blue Shield is changing in 2026, as several major BCBS affiliates are dropping or restricting GLP-1 weight-loss coverage entirely as part of cost-control measures